Search
Research
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers Aged 18-36 monthsA bivalent, recombinant, factor H-binding protein (rLP2086) vaccine was developed to protect against invasive Neisseria meningitidis serogroup B (MnB) in...
Research
Pandemic influenza H1N1 2009 infection in Victoria, AustraliaConflicting findings regarding the level of protection offered by seasonal influenza vaccination against pandemic influenza H1N1 have been reported.
Research
A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults:Neisseria meningitidis is a leading cause of meningitis and septicaemia, but a broadly-protective vaccine against endemic serogroup B disease is not licensed...
Research
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV typesWe evaluated the efficacy of the human papillomavirus HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types.
Research
Crowding and other strong predictors of upper respiratory tract carriage of otitis media-relatedWe investigated predictors of nasopharyngeal carriage in Australian Aboriginal and non-Aboriginal children.
Research
Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcalThe impact of the 23vPPV booster on IPD incidence among Australian Indigenous children is unclear from regional reports of small case numbers.
Research
Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescentsThis trial evaluated the lot consistency, early immune responses and safety of the vaccine against serogroup B Neisseria meningitidis (4CMenB) - in 11 to 17...
Research
Comparison of text-messaging to voice telephone interviews for active surveillance of adverse events following immunisation.This study was designed to compare data collected via SMS and telephone for the purposes of monitoring vaccine safety.
Research
Antibody persistence in Australian adolescents following meningococcal C conjugate vaccinationIn Australia, following the introduction of serogroup C meningococcal (MenC) conjugate vaccine for toddlers and catch-up immunization through adolescence,...
Research
A randomized phase I study of the safety and immunogenicityIn this study of healthy adults aged 50-85 and 18-24 years, SA3Ag elicited a rapid and robust immune response and was well tolerated, with no notable safety...